New combo offers hope for aggressive lymphoma in diverse patients

NCT ID NCT04981795

Completed Disease control Sponsor: Incyte Corporation Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tracked 102 US adults with relapsed or refractory diffuse large B-cell lymphoma (a type of blood cancer) who were treated with a combination of tafasitamab and lenalidomide. The goal was to see how safe and effective this treatment is, especially for racial and ethnic minority patients. Researchers measured side effects, tumor shrinkage, and how long patients lived without the cancer getting worse.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma lymphoma relapsed/refractory diffuse large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIFFUSE LARGE B-CELL LYMPHOMA

Contacts and locations

Locations

Alabama Oncology

Birmingham, Alabama, 35211, United States
American Oncology Partners of Maryland PA

Bethesda, Maryland, 20817, United States
Clearview Cancer Institute

Huntsville, Alabama, 35805, United States
Duke University

Durham, North Carolina, 27705, United States
Froedtert & Medical College Clinics

Milwaukee, Wisconsin, 53226, United States
Henry Ford Health System

Detroit, Michigan, 48202, United States
Integris Cancer Institute of Oklahoma

Oklahoma City, Oklahoma, 73142, United States
Lankenau Medical Center

Wynnewood, Pennsylvania, 19096, United States
Leo Jenkins Cancer Center/ECU School of Medicine

Greenville, North Carolina, 27858, United States
Levine Cancer Institute

Charlotte, North Carolina, 28204, United States
McFarland Clinic P.C.

Ames, Iowa, 50010, United States
Mercy Medical Center

Canton, Ohio, 44708, United States
Mission Cancer and Blood

Des Moines, Iowa, 50309, United States
Morristown Medical Center

Morristown, New Jersey, 07960-6136, United States
Ohio Health Marion Area Physicians

Marion, Ohio, 43302, United States
Rutgers Cancer Institute of New Jersey

New Brunswick, New Jersey, 08903-2681, United States
Thomas Jefferson University

Philadelphia, Pennsylvania, 19107, United States
Tri County Hematology & Oncology Associates, Inc

Massillon, Ohio, 44646, United States
Tulane Cancer Center

New Orleans, Louisiana, 70112, United States
UW Medicine

Seattle, Washington, 98109, United States
University of California, Irvine Medical Center

Orange, California, 92868, United States
University of Michigan Comprehensive Cancer Center Michigan Medicine

Ann Arbor, Michigan, 48109, United States
University of Texas MD Anderson Cancer Center

Houston, Texas, 77030, United States
VA Medical Center - Durham

Durham, North Carolina, 27705, United States
Westchester Medical Center

Hawthorne, New York, 10532, United States
Yakima Valley Memorial Hospital/North Star Lodge

Yakima, Washington, 98902, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.